Overview of HIV Prevention
Summary
- FDA approved emtricitabine/tenofovir DF to reduce the risk of sexually acquired HIV infection in adults at high risk in 2012 based on favorable results from several studies[Grant 2010; Baeten 2012; Thigpen 2012]
- Several clinical trials have established the efficacy of tenofovir DF–containing PrEP
- In 2018, FDA expanded indication for oral emtricitabine/tenofovir DF PrEP to include at-risk adolescents when used in combination with safer sex practices[FDA FTC TDF]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Biomedical Prevention